Certificate was obtained in accordance with the relevant laws in the United Kingdom for the experimental use of Photofrin for photodynamic therapy in pituitary tumors.
After I received the appropriate regulatory approvals, eight patients beetween 29 and 69 years of age who had recurrent pituitary adenomas and who had undergone previous surgery and radiation therapy were recruited ( Table 1) . The experimental nature of the treatment and the possible side effects were discussed with each patient and his relatives and informed consent was obtained. Pregnant women and patients younger than 21 years of age were excluded.
Drug Dosage and Administration
Photofrin was supplied as a freeze-dried dark brown powder in light-proof boxes by QLT Pharmaceuticals, Kattendijke, The Netherlands. It was reconstituted by mixing 75 mg dry powder (one vial) with 31.8 ml 5% dextrose, giving a final drug concentration of 2.5 mg/ml. This solution was administered by slow intravenous injection at a dose of 2 mg/kg body weight 48 hours before transsphenoidal hypophysectomy in all eight patients. After injection of the drug, patients were placed in rooms with subdued light and were advised to avoid direct sunlight and intense artificial light for approximately 8 weeks.
Intraoperative Collection of Samples
Transsphenoidal hypophysectomy was performed 48 hours after injection of the Photofrin solution. The surgical procedure followed the standard steps of endonasal transsphenoidal hypophysectomy, except that at the end of tumor resection intraoperative photodynamic therapy with 630-nm laser light was performed, delivering 75 J/cm 2 to the tumor bed (75 mW/cm 2 over 1000 seconds). During the procedure, venous blood, pituitary adenoma tissue, muscle, fat, and skin samples were obtained for determination of Photofrin concentration. The muscle and fat were obtained from the right thigh and were used for packing the sphenoid and tumor bed; approximately 5 g of tissue were collected for measurement of the Photofrin level. Immediately after collection the specimens were placed in a cooled light-proof container and transferred to the laboratory. Specimens not analyzed immediately were stored in liquid nitrogen.
Method of Photofrin Assay
The photofrin level in the pituitary, muscle, fat, skin, and plasma was determined using the method described by Vernon, et al. 43 In common with other fluorometric assays, this method involved the extraction of Photofrin oligomers from tissue or plasma, which are then hydrolyzed to monomeric porphyrins and the amount is measured using fluorescence analysis. Unlike other methods, however, this one calibrates for the acid-stable fraction, which may constitute up to 40% of the drug, and the monomeric species, which are invariably cleared shortly after injection. This method, therefore, provides an accurate measurement of the amount of drug in plasma or tissue. The details are reported in Vernon, et al., but the essential steps for the use of this method for plasma start with precipitation of the proteins out of 100 l plasma with 5 ml of a mixture of ethyl acetate and acetic acid (4:1 vol/vol). After centrifugation, 4 ml of the supernatant is mixed with 1 M hydrochloric acid, which separates the mixture into two phases: an upper layer containing contaminating heme and bilirubin and a lower aqueous layer containing the porphyrins. The top layer is discarded and the oligomeric porphyrins in the aqueous layer are hydrolyzed to monomers by boiling in a water bath for 30 minutes. The aqueous mixture is cooled to room temperature and the fluorescence is measured (400 nm excitation with 596 nm emission). A blank control is prepared by treating the aforementioned reagents in a similar fashion but without the plasma. A standard solution of Photofrin from the same batch as that given to the patient is mixed with 1 M hydrochloric acid and used to calibrate the extraction process. The procedure is similar for the tissues, but 100 mg of tissue is first dissolved in 1 ml of 1 M NaOH by incubating the mixture overnight in a shaking water bath at 40˚C. The alkali is neutralized with 50 l of phosphoric acid. The rest of the procedure is similar to that used with the plasma. Calibration curves that accommodate for the acid-stable component as described by Vernon, et al., were used to calculate the amount of Photofrin in the plasma and tissues.
Data Analysis
The SPSS program for Windows (version 11) was used to analyze all data. The paired (dependent) Student t-test was used to compare the mean Photofrin levels in different tissues and the measured levels of Photofrin were adjusted for within-subject design for the error bars as suggested by Loftus and Masson. 31 A 5% level of significance (␣-error, two-tailed) was accepted for differences between means, and the 95% CIs for the means are indicated in parentheses. in two of them, leaving six patients with a complete set of samples (pituitary, muscle, fat, and serum) that were analyzed for this study. The clinical outcome has been reported elsewhere. 32 The mean of two determinations in plasma and tissue was taken as the final level of Photofrin. The clinical characteristics of the six patients are shown in Table 1 . The Photofrin level in pituitary adenoma tissue, in nanograms of oligomer per milligram of tissue, ranged from 3.48 to 11.99 (mean 6.87; 95% CI 3.99-9.75). In muscle the level of Photofrin ranged from 0.69 to 3.86 ng/mg of tissue (mean 2.24; 95% CI 1.28-3.2) and in fat the drug level ranged from 0.59 to 5.48 ng/mg of tissue (mean 2.54; 95% CI 0.66-4.42). The mean drug level in pituitary adenoma tissue was therefore significantly higher than the concentration in muscle (mean 2.24, p = 0.008; Fig. 1 upper) and fat (mean 2.54; p = 0.007; Fig. 1 center) . The drug concentration in pituitary adenoma tissue was not significantly different, however, from the level in plasma (range 4.59-12.57 g/ml, mean 7.65; p = 0.558); the adjusted error bars for plasma and pituitary adenoma tissue were almost identical (Fig. 1 lower) . The mean uptake ratio of pituitary adenoma tissue to muscle was 3.3 (range 1.96-5.54) and for fat it was 4.02 (range 1.84-6.47). Skin specimens were available in four patients and these showed a mean uptake of 2.19 ng/mg (range 0.67-3.16) with a mean pituitary skin uptake ratio of 3.4 (range 1.1-5.7).
Results

Eight patients were recruited for this
Discussion
Photofrin Uptake
I chose Photofrin as the photosensitizer because nearly four decades of clinical use 29 attest to its safety and it is one of the most widely used and studied photosensitizers in that time. 8 Laws, et al., 25 remarked on the use of hematoporphyrin derivative to localize pituitary adenomas in vivo, but as far as I am aware this study is the first report of the quantitative determination of the in vivo uptake of Photofrin by human pituitary adenoma tissue. I have demonstrated that weight for weight, pituitary adenomas take up Photofrin to more than three times the level in normal tissues such as muscle and fat. Several authors have confirmed that the normal brain takes up less Photofrin than muscle; 2,3, 13,27 hence it would be reasonable to expect that the drug level in the normal brain of the patients presented here would be less than in muscle. The effect of photodynamic therapy on the normal brain has been the subject of considerable controversy, however: in early reports it was suggested that there was very little uptake (and hence no photodynamic therapy-induced damage), 20 yet several authors have demonstrated dose-dependent brain tissue damage from Photofrin photodynamic therapy. 6, 26 It was not possible or ethically desirable to compare the uptake in pituitary adenoma tissue with normal pituitary glands, because in this group of patients there was very little normal pituitary tissue left after repeated surgery and radiation therapy. The levels of Photofrin we obtained in pituitary adenoma tissue were nearly one and a half times those reported for gliomas in vivo. 15, 19 This is not surprising because Photofrin uptake in the central nervous system parallels blood-brain barrier permeability. 17, 19 Thus my findings indicate a need to consider reduced doses of Photofrin for photodynamic therapy in pituitary adenomas, with the potential benefit of reduced skin sensitivity and reduced risk of damage to the adjacent normal brain. 12 
Mechanism of Preferential Uptake
It has been suggested that porphyrins are taken up by tumors via low-density lipoprotein receptor-mediated endocytosis. 18 In addition, several other factors have been proposed, including the decreased conversion of porphyrins to heme in tumors (due to low ferrochelatase activity in tumor) and reduced or absent lymphatic drainage in tumors. 21, 42 Nevertheless, it is much more likely that the nearly identical levels in plasma and pituitary adenoma seen in this study are the result of free equilibration along a concentration gradient, given the very porous capillaries in pituitary tissue. The lower levels in muscle and fat, however, could be the result of both lower uptake and conversion of Photofrin to heme. Attempts to identify the subcellular localization of Photofrin in pituitary adenoma tissue by using fluorescence microscopy and immunocytochemical markers for factor VIII and macrophages did not yield consistent results (U. Igbaseimokumo, unpublished data). Reliable data from this procedure would have offered important clues to the site of action and mechanisms involved in Photofrin-photodynamic therapy in pituitary adenomas because singlet O 2 generated during photoactivation invariably acts at the site of production and does not last long enough to diffuse far.
34,40
Limitations of Fluorometric Assay
Photofrin is a complex mixture of monomeric and oligomeric porphyrin molecules. 9 The highly fluorescent monomeric species (10-20%) in Photofrin are cleared shortly after intravenous injection (within 1 hour or so), leaving the nonfluorescent oligomeric portion in plasma and localized to tissue. 21 Most fluorometric methods depend on the extraction and hydrolysis of the oligomers to monomeric porphyrins, which are measured using fluorometric analysis. Unfortunately, up to 40% of the oligomeric porphyrins in tissue or plasma are acid-stable and nonfluorescent in aqueous solution. The method published by Vernon, et al., 43 accounts for these limitations by using Photofrin from the same batch of drug as that administered to the patient to calibrate the extraction process as well as correct for the monomers; hence, this modified process is an accurate method of Photofrin assay for clinical use. Furthermore, drug determination by this method has been shown to have a linear relationship with drug determinations made using radioactivity.
Variation in Photofrin Level From Patient to Patient
Although the variation in the level of Photofrin from patient to patient as seen in this study (3.48-11.99 ng/mg of tissue, mean 6.96) is a common observation, there are as yet no satisfactory explanations. 2, 15 Several reasons, however, may apply: Photofrin is a complex mixture of monomeric and oligomeric porphyrins whose biodistribution is determined by the hydrophobicity of the monomeric species, the charge distribution, and the pK a value along with the aggregation/dissociation constant and molecular weight of oligomers. After intravenous injection, Photofrin is more than 90% protein bound, with the monomeric species primarily bound to albumin and the oligomers bound to low-and high-density lipoprotein. Thus, the variations in the amount of Photofrin from patient to patient that were seen in this study and other reports 2, 27, 35 probably reflect variations in the interaction between different patients and the drug due to differences in the aforementioned properties. Interpretation of data is further complicated by the complexity of Photofrin, a mixture whose composition may vary slightly from one batch to another, in addition to possible alteration occurring during transportation, storage, and reconstitution. 4 In a pharmacokinetic study involving 12 patients with lung cancer who were given 2 mg/kg of Photofrin intravenously, the peak serum concentration varied from 39.3 to 222 g/ ml (these data appear in QLT Phototherapeutics, Inc., Clinical Investigator's Brochure, December 1994).
Long-Term Follow Up
Although the primary purpose of this study was to establish the scientific basis for the feasibility study reported earlier, 32 these six patients represent the longest follow up to date; hence, their long-term clinical course is summarized here. All six patients had undergone surgery and radiation therapy initially and then developed recurrent tumors. The mean time from the last treatment to recurrence was reported to be 2 years (9-66 months) by Marks, et al. 32 It is highly remarkable that at 6 years of follow up after repeated surgery and intraoperative photodynamic therapy there has been no recurrence or progression in any of the five surviving patients. The progressive collapse and destruction of the infiltrated dural capsule, which marks the outline of the preoperative tumor mass (arrows in Fig. 2A ) on early serial imaging, indicates that this was the effect of photodynamic therapy (Fig. 2B ). Although the current work provides a clear scientific basis for the application of photodynamic therapy as adjuvant treatment for pituitary tumors, longterm efficacy will need to be confirmed in a randomized study in which the long-term outcome (clinical and radiological) in untreated patients is compared with those who received adjuvant intraoperative photodynamic therapy. One patient died of unrelated causes in January 2000, 3 years after receiving intraoperative photodynamic therapy. In the remaining five patients, all of whom suffered hypopituitarism prior to photodynamic therapy, there has been no change in hormone replacement needs and the improvement in vision has been maintained.
Conclusions
In this study I have shown that the in vivo uptake of Photofrin by pituitary adenoma tissue is three times the concentration in normal tissues such as muscle and fat and is higher than the uptake reported for gliomas. Because the concentration in the pituitary tissue was virtually identical to the level in plasma, it appears likely that in the pituitary Photofrin equilibrates with tissue along a concentration gradient.
